Skip to main content
. Author manuscript; available in PMC: 2024 Jan 14.
Published in final edited form as: Clin Cancer Res. 2023 Jul 14;29(14):2651–2667. doi: 10.1158/1078-0432.CCR-21-3521

Figure 1. Overview of study and ALK aberrations in GBM.

Figure 1.

A. ALK aberration screening was performed on 371 GBMs and HGGs using orthogonal assays including Whole Genome Sequencing (WGS), RNA sequencing (RNAS), Targeted Exome Sequencing (TES), immunohistochemistry (IHC), break apart FISH probes flanking 3’ and 5’ ALK regions, and copy number arrays (array CGH and SNP array).

B. Oncoprint summary of ALK alterations in 198 GBMs with sequencing data (WGS or TES). 11/198 GBMs were found to have ALK rearrangements in this cohort. Tumors for which data are unavailable are designated N/A.

C. Schematic structure of ALK fusion proteins identified in our GBM cohort.